Composition for prevention or treatment of liver injury or colitis comprising polyscias fruticosa extract as active ingredient
Polyscias fruticosa extract addresses the inadequacies in liver damage and colitis treatments by reducing inflammation and restoring antioxidants, effectively managing liver damage and colitis through its inclusion in pharmaceutical and food compositions.
Patent Information
- Application Number
- PCT/KR2024/007488
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-02
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-05
AI Technical Summary
Current treatments for liver damage and colitis are inadequate in addressing the underlying inflammatory and oxidative stress issues, particularly in models induced by D-Galactosamine/Lipopolysaccharide and Dextran Sulfate Sodium, which cause significant hepatotoxicity and colonic inflammation.
A pharmaceutical and health functional food composition containing Polyscias fruticosa extract or its fractions, which are extracted using solvents like ethanol and further purified, are administered to reduce inflammation, restore antioxidant levels, and modulate signaling pathways such as NF-κB and Nrf2, thereby providing hepatoprotection and colitis treatment.
The Polyscias fruticosa extract significantly reduces liver damage and colitis symptoms by inhibiting inflammatory cytokines, restoring antioxidant enzymes, and improving histopathological scores, demonstrating its potential as a therapeutic agent for liver protection and colitis management.
Smart Images

Figure KR2024007488_05122024_PF_FP_ABST
Abstract
Description
Composition for preventing or treating liver damage or colitis containing polysia extract as an active ingredient
[0001] The present invention relates to a composition for preventing or treating liver damage or colitis, comprising a polysia extract as an active ingredient.
[0002] The liver stores and circulates blood, regulates blood volume, and carries out detoxification. It is also closely linked to mental function. Due to the constant exposure to various pollutants and toxic substances resulting from industrialization, the liver is constantly under pressure to detoxify. Mental stress is also known to cause liver damage. Reduced detoxification due to liver damage can disrupt the immune system, leading to other diseases. Commonly used agents known to induce hepatotoxicity include carbon tetrachloride and D-galactosamine.
[0003] Bile contains components such as bile acids, phospholipids, bilirubin, GSH, and electrolytes, and is not only a passage for excretion of toxic substances and fat breakdown products, but also participates in the digestion and absorption of fat, performs various physiological functions, excretes endogenous waste products such as bilirubin, drugs, and various toxic substances, increases normal fat absorption in the intestines, and plays a central role in maintaining the balance of cholesterol metabolism in the human body.
[0004] Meanwhile, galactosamine / lipopolysaccharide is widely used as one of the representative cholestatic liver disease induction models, and among these, galactosamine depletes UTP and UDP-glucuronic acid in liver tissue, thereby inhibiting protein production, depleting GSH (Glutathione), a liver protective substance, and inhibiting glucuronidation involved in the excretion of foreign substances, thereby inducing hepatotoxicity. Its histological characteristics include cell necrosis of parenchymal tissues and observation of inflammatory cell infiltration.
[0005] In addition, lipopolysaccharide (LPS) rapidly increases the portal vein inflow of endotoxin containing LPS, which increases the secretion of tumor necrosis factor-α (TNF-α) due to the activation of inflammatory cells in the liver, causing fulminant hepatitis, which pathologically reduces the expression of hepatocyte transport proteins in acute and chronic inflammation in the liver, and this reduction in transport proteins leads to impaired bile excretion, which increases the expression of alkaline phosphatase (ALP) and γ-glutamyl transpeptidase, which are hematological indicators of cholestatic liver disease.
[0006] Meanwhile, Polyscias (Polyscias fruticosa) is an evergreen shrub of the Araliaceae family that grows in hot and humid regions along the Pacific coast of Southeast Asia. Approximately 80 species are known to grow in their native habitat, and about eight of these are cultivated for horticulture. The scientific name "Polyscias" means "lush leaves," and it is also commonly known as Aralia. In Asian countries, the leaves of Polyscias fruticosa are known to be used as a tonic, anti-inflammatory, anti-toxic, and antibacterial ointment, but its hepatoprotective and colitis-treating effects are completely unknown.
[0007] The purpose of the present invention is to provide a pharmaceutical composition for preventing or treating liver damage or colitis, which contains an extract of Polyscias fruticosa or a fraction thereof as an active ingredient.
[0008] In addition, another object of the present invention is to provide a health functional food composition for preventing or improving colitis, which contains an extract of Polyscias fruticosa or a fraction thereof as an active ingredient.
[0009] In addition, another object of the present invention is to provide a health functional food composition for protecting the liver, which comprises an extract of Polyscias fruticosa or a fraction thereof as an active ingredient.
[0010] In addition, another object of the present invention is to provide a method for preventing or treating liver damage or colitis, comprising a step of administering the pharmaceutical composition to a subject.
[0011] To achieve the above purpose, the present invention provides a pharmaceutical composition for preventing or treating liver damage or colitis, comprising a Polyscias fruticosa extract or a fraction thereof as an active ingredient.
[0012] Next, the present invention provides a health functional food composition for preventing or improving colitis, comprising a Polyscias fruticosa extract or a fraction thereof as an active ingredient.
[0013] Furthermore, the present invention provides a health functional food composition for hepatoprotection comprising an extract of Polyscias fruticosa or a fraction thereof as an active ingredient.
[0014] Finally, the present invention provides a method for preventing or treating liver damage or colitis, comprising administering the pharmaceutical composition to a subject.
[0015] The Polyscias fruticosa extract or its fraction according to the present invention exhibited excellent anti-inflammatory effects in animal models of liver damage and colitis, and thus can be usefully utilized as an active ingredient in pharmaceutical compositions and health functional food compositions for preventing, improving, or treating liver damage or colitis. Furthermore, as an alternative crop for responding to climate change, the subtropical crop Polyscias fruticosa can be proposed as a new, high-value-added crop that can generate farm income.
[0016] Figure 1 is a diagram showing the GC-MS analysis results of the hexane fraction of P. fruticosa in one embodiment of the present invention.
[0017] FIG. 2 is a diagram showing the GC-MS analysis results of a P. fruticosa DCM fraction in one embodiment of the present invention.
[0018] FIG. 3 and FIG. 4 are diagrams showing the results of histopathological analysis according to administration of P. fruticosa ethanol extract and its fat-soluble fraction to liver tissue in one embodiment of the present invention.
[0019] FIG. 5 is a diagram showing the results of measuring ALT and AST enzymes in liver tissue according to administration of an ethanol extract of P. fruticosa and its fat-soluble fraction in one embodiment of the present invention.
[0020] FIG. 6 and FIG. 7 are diagrams showing the results of measuring the expression levels of inflammatory cytokines and NLRP3 inflammasome-related proteins in liver tissue according to administration of P. fruticosa ethanol extract and its fat-soluble fraction in one embodiment of the present invention.
[0021] FIG. 8 and FIG. 9 are diagrams showing the results of measuring the expression level of proteins related to the NF-κB signaling pathway according to administration of an ethanol extract of P. fruticosa and a fat-soluble fraction thereof in liver tissue in one embodiment of the present invention.
[0022] Figures 10 to 12 are diagrams showing the results of measuring the level of antioxidant enzyme protein expression and evaluating SOD activity according to administration of P. fruticosa ethanol extract and its fat-soluble fraction to liver tissue in one embodiment of the present invention.
[0023] FIG. 13 and FIG. 14 are diagrams showing the results of measuring the expression level of proteins related to the Nrf2 signaling pathway according to administration of P. fruticosa ethanol extract and its fat-soluble fraction to liver tissue in one embodiment of the present invention.
[0024] Figures 15 to 19 are diagrams showing the results of histological analysis and inflammation scale evaluation according to administration of P. fruticosa ethanol extract and its fat-soluble fraction to colon tissue in one embodiment of the present invention.
[0025] Figures 20 to 22 are diagrams showing the results of measuring the expression levels of inflammatory cytokines and NLRP3 inflammasome-related proteins in colon tissue according to administration of P. fruticosa ethanol extract and its fat-soluble fraction in one embodiment of the present invention.
[0026] FIG. 23 and FIG. 24 are diagrams showing the results of measuring the expression levels of antioxidant enzyme proteins and Nrf2 signaling pathway-related proteins according to administration of P. fruticosa ethanol extract and its fat-soluble fraction to colon tissue in one embodiment of the present invention.
[0027] Figures 25 and 26 are diagrams showing the results of measuring the level of tight junction protein expression in colon tissue according to the administration of P. fruticosa ethanol extract and its fat-soluble fraction in one embodiment of the present invention.
[0028] Hereinafter, the present invention will be described in detail with reference to the attached drawings, using exemplary embodiments. However, the following exemplary embodiments are provided as illustrative examples of the present invention. If a detailed description of a technology or configuration well known to those skilled in the art is judged to unnecessarily obscure the gist of the present invention, such detailed description may be omitted, and the present invention is not limited thereby. The present invention is capable of various modifications and applications within the scope of the following claims and equivalents interpreted therefrom.
[0029] In addition, the terms used in this specification are terms used to appropriately express preferred embodiments of the present invention, and may vary depending on the intention of the user or operator, or the customs of the field to which the present invention belongs. Therefore, the definitions of these terms should be determined based on the contents throughout this specification. Throughout the specification, when a part is said to "include" a certain component, this does not mean that other components are excluded, but rather that other components may be included, unless specifically stated otherwise.
[0030] Throughout this specification, '%' used to indicate the concentration of a particular substance means solid / solid (w / w) %, solid / liquid (w / v) %, and liquid / liquid (v / v) %, unless otherwise stated.
[0031]
[0032] In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating liver damage or colitis, comprising an extract of Polyscias fruticosa or a fraction thereof as an active ingredient.
[0033] In one embodiment of the present invention, the Polyscias fruticosa extract may be prepared by extracting from at least one selected from the group consisting of roots, stems, leaves, flowers, and fruits, and may preferably be prepared by extracting from roots, but is not limited thereto.
[0034] The extract according to the present invention can be obtained by extracting and separating from nature using extraction and separation methods known in the art, and the "extract" defined in the present invention is extracted from Polyscias fruticosa using an appropriate solvent, and includes, for example, a crude extract, a polar solvent-soluble extract, or a non-polar solvent-soluble extract. Any organic solvent acceptable in terms of food science / pharmaceutics / cosmetics may be used as a suitable solvent for extracting the extract from the above Polyscias fruticosa, and water or an organic solvent may be used, and is not limited thereto, for example, purified water, alcohols having 1 to 4 carbon atoms including methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, and cyclohexane, etc., may be used alone or in mixtures, and preferably ethanol, and more preferably 70 to 100% (v / v) ethanol may be used as the solvent.
[0035] Any one of the following extraction methods may be selected and used: hot water extraction, cold immersion extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, dissolution, and pressing. Furthermore, the desired extract may be subjected to additional conventional fractionation processes and purified using conventional purification methods.
[0036] There is no limitation on the method for preparing the extract of the present invention, and any known method can be used. For example, the extract included in the composition of the present invention can be prepared in a powder form by additional processes such as reduced pressure distillation and freeze drying or spray drying of the primary extract extracted by the above-mentioned hot water extraction or solvent extraction method. In addition, the primary extract can be obtained by further purifying fractions using various chromatography methods such as silica gel column chromatography, thin layer chromatography, and high performance liquid chromatography. Therefore, in the present invention, the extract is a concept that includes all extracts, fractions, and purified products obtained at each stage of extraction, fractionation, or purification, as well as their dilutions, concentrates, or dried products.
[0037] The term "fraction" of the present invention means a result obtained by performing fractionation to separate a specific component or a specific group of components from a mixture containing various components.
[0038] In the present invention, the fractionation method for obtaining the above fraction is not particularly limited and can be performed according to a method commonly used in the art. Non-limiting examples of the fractionation method include a fractionation method performed by treating various solvents, an ultrafiltration fractionation method performed by passing the fraction through an ultrafiltration membrane having a certain molecular weight cut-off value, a chromatographic fractionation method performed by performing various chromatographies (designed for separation according to size, charge, hydrophobicity, or affinity), and combinations thereof. Specifically, a method of obtaining a fraction from an extract obtained by extracting Polyscias fruticosa of the present invention by treating the extract with a predetermined solvent can be exemplified.
[0039] In the present invention, the type of fractionation solvent used to obtain the fraction is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the fractionation solvent include polar solvents such as water and alcohols having 1 to 4 carbon atoms; non-polar solvents such as hexane, ethyl acetate, chloroform, dichloromethane, benzene, toluene, acetone, carbon tetrachloride, ether, methylene, and the like; or mixed solvents thereof. These may be used alone or in combination of one or more thereof, but are not limited thereto. Preferably, a non-polar solvent, more preferably, hexane or dichloromethane, can be used, but are not limited thereto.
[0040] In addition, the above extract or fraction may be manufactured and used in the form of a dry powder after extraction, but this is not limited thereto.
[0041] In one embodiment of the present invention, the liver damage may be induced by, but is not limited to, D-GalN (D-Galactosamine) and LPS (Lipopolysaccharide).
[0042] Additionally, the above D-GalN and LPS are known to form typical hepatocyte necrosis and apoptosis and cause dysfunction of multiple organs.
[0043] In one embodiment of the present invention, the colitis may be induced by, but is not limited to, dextran sulfate sodium (DSS).
[0044] In one embodiment of the present invention, the colitis may be selected from the group consisting of ulcerative colitis, inflammatory bowel disease, acute colitis, bacterial colitis, viral colitis, pseudomembranous colitis, chronic colitis, Crohn's disease, ischemic colitis, Behcet's colitis, drug-induced colitis, collagenous colitis, lymphocytic colitis, and radiation colitis, but is not limited thereto.
[0045] The term "prevention" as used herein refers to any action that reduces the frequency or severity of a pathological phenomenon. Prevention may be complete or partial. In this case, it may refer to a reduction in liver damage or colitis symptoms within a subject compared to when the composition was not used.
[0046] The term "treatment" above refers to any clinical intervention intended to alter the natural processes of the target or cells to be treated, and may be performed during or to prevent the progression of a clinical pathological condition. The desired therapeutic effect may include preventing the occurrence or recurrence of a disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the progression of the disease, alleviating or temporarily alleviating the disease state, or improving the prognosis.
[0047] The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and not causing side effects. The effective dosage level may be determined based on factors including the patient's health condition, the type and severity of the disease, the activity and sensitivity of the drug, the method of administration, the time of administration, the route and excretion rate, the duration of treatment, drugs used in combination or simultaneously, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or in multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with the minimum amount without side effects, and this can be easily determined by those skilled in the art.
[0048] The composition according to the present invention may comprise a pharmaceutically effective amount of a Polyscias fruticosa extract alone or may comprise one or more pharmaceutically acceptable carriers, excipients, or diluents. The pharmaceutically effective amount as described above refers to an amount sufficient to prevent, improve, and treat symptoms of liver damage or colitis. The term "pharmaceutically acceptable" as described above refers to a composition that is physiologically tolerable and does not typically cause gastrointestinal upset, allergic reactions such as dizziness, or similar reactions when administered to humans.
[0049] Additionally, compositions containing pharmaceutically acceptable carriers may be administered orally or parenterally in various dosage forms. When formulated, they may be prepared using commonly used diluents or excipients, such as fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants. The carrier, excipient and diluent may be at least one selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, saline solution, methyl hydroxybenzoate, propyl hydroxy benzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, propylene glycol and liquid paraffin, but is not limited thereto, and any conventional carrier, excipient or diluent may be used. The above components may be added independently or in combination to the active ingredient, Polyscias fruticosa extract.
[0050] In addition, the pharmaceutical composition of the present invention may have any one dosage form selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, oral solutions, emulsions, syrups, sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. As a base for the suppository, witepsol, macrogol, tween 61, cocoa butter, laurin butter, glycerol, gelatin, etc. can be used.
[0051] The Polyscias fruticosa extract of the present invention can be administered in various oral and parenteral formulations during clinical administration, and when formulated, it is manufactured using diluents or excipients such as commonly used fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants.
[0052] Solid preparations for oral administration include tablets, tablets, powders, granules, capsules, troches, etc., and these solid preparations are prepared by mixing one or more Polyscias fruticosa extracts of the present invention with at least one excipient, such as starch, calcium carbonate, sucrose, lactose, or gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, or syrups, and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, flavoring agents, and preservatives may be included.
[0053] Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solutions and suspensions can include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases include witepsol, macrogol, Tween 61, cocoa butter, laurin, glycerol, and gelatin.
[0054] In addition, the effective dosage of the Polyscias fruticosa extract of the present invention for the human body may vary depending on the patient's age, body weight, sex, dosage form, health condition, and disease severity, and is generally about 0.001-100 mg / kg / day, and preferably 0.01-35 mg / kg / day. For an adult patient weighing 70 kg, the dosage is generally 0.07-7000 mg / day, and preferably 0.7-2500 mg / day. Depending on the judgment of a doctor or pharmacist, it may be administered once or several times a day at regular intervals.
[0055] The pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, or biological response modifiers.
[0056] The pharmaceutical composition of the present invention can also be provided in the form of an external preparation containing a Polyscias fruticosa extract as an active ingredient.
[0057] When the pharmaceutical composition of the present invention is used as a skin external preparation, it may additionally contain adjuvants commonly used in the field of dermatology, such as any other ingredients commonly used in skin external preparations, such as fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic emulsifiers, nonionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, blocking agents, humectants, essential oils, dyes, pigments, hydrophilic activators, lipophilic activators, or lipid vesicles. In addition, the above ingredients may be introduced in amounts commonly used in the field of dermatology. When the pharmaceutical composition of the present invention is provided as a skin external preparation, it may be in the form of an ointment, patch, gel, cream, or spray, but is not limited thereto.
[0058]
[0059] In one aspect, the present invention relates to a food composition for protecting the liver or preventing or improving colitis, comprising an extract of Polyscias fruticosa or a fraction thereof as an active ingredient.
[0060] Since the food composition of the present invention includes the above-described Polyscias fruticosa extract and fractions thereof, descriptions of the overlapping contents with the above-described Polyscias fruticosa extract and fractions thereof of the present invention are omitted to avoid excessive complexity of the present specification due to descriptions of overlapping contents.
[0061] The term “hepatoprotection” used in the present invention means that the Polyscias fruticosa extract or its fraction of the present invention has an effect of protecting liver cells by increasing antioxidant activity and suppressing inflammation.
[0062] The food composition of the present invention can be formulated into various forms such as tablets, pills, granules, capsules, liquid preparations, and beverages and added to foods. There is no particular limitation on the type of food. Examples of foods to which the Polyscias fruticosa extract of the present invention can be added include drinks, meat, sausages, bread, biscuits, rice cakes, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, alcoholic beverages, vitamin complexes, dairy products, and dairy products, and includes all health foods and health functional foods in the conventional sense.
[0063] The health food and health functional food compositions containing the Polyscias fruticosa extract according to the present invention can be added directly to foods or used together with other foods or food ingredients, and can be used appropriately according to conventional methods. The amount of the Polyscias fruticosa extract mixed can be appropriately determined depending on its intended use (prevention or improvement). Generally, the amount of the composition in the health food and health functional food can be added in an amount of 0.1 to 90 parts by weight based on the total food weight. However, in the case of long-term intake for the purpose of maintaining or regulating health, the amount can be below the above range, and since there is no problem in terms of safety, the active ingredient can also be used in an amount above the above range.
[0064] The health food and health functional food composition of the present invention contains the Polyscias fruticosa extract of the present invention as an essential ingredient in the indicated proportions, and has no particular limitations on other ingredients, and may contain various flavoring agents or natural carbohydrates as additional ingredients, like conventional beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose, etc.; disaccharides such as maltose, sucrose, etc.; and polysaccharides such as dextrin, cyclodextrin, etc., and conventional sugars, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (thaumatin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g, per 100 g of the health functional food composition of the present invention.
[0065] In addition to the above, the health food and health functional food composition containing the Polyscias fruticosa extract of the present invention may contain various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the health food and health functional food composition of the present invention may contain fruit pulp for producing natural fruit juice and fruit juice drinks and vegetable drinks.
[0066] These ingredients can be used independently or in combination. The proportion of these additives is not particularly critical, but is typically selected within the range of 0.1 to about 20 parts by weight per 100 parts by weight of the health food and health functional food composition containing the Polyscias fruticosa extract of the present invention.
[0067]
[0068] Finally, the present invention provides a method for preventing or treating liver damage or colitis, comprising administering the pharmaceutical composition to a subject.
[0069] The term "subject" as used in the present invention refers to a subject requiring a method for preventing, controlling, or treating a disease, and may be used without limitation as a human, dog, monkey, cat, rodent, such as a mouse, genetically modified mouse, etc. More specifically, it refers to a mammal such as a human or non-human primate, mouse, rat, dog, cat, horse, cow, etc.
[0070] The pharmaceutical composition of the present invention can be administered in a therapeutically effective amount or a pharmaceutically effective amount.
[0071] In the present invention, the term "therapeutically effective amount" means the amount of a pharmaceutically acceptable salt of a composition effective in preventing or treating a target disease, and the therapeutically effective amount of the composition of the present invention may vary depending on various factors, such as the administration method, the target site, the condition of the patient, etc. Therefore, the dosage for use in humans should be determined as an appropriate amount by taking both safety and efficacy into consideration. It is also possible to estimate the amount to be used in humans from the effective amount determined through animal testing. Such considerations in determining the effective amount are described, for example, in Hardman and Limbird, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. (2001), Pergamon Press; and E.W. Martin ed., Remington's Pharmaceutical Sciences, 18th ed. (1990), Mack Publishing Co.
[0072] In the present invention, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and not causing side effects, and the effective dosage level can be determined according to factors including the patient’s health condition, type and severity of the disease, activity of the drug, sensitivity to the drug, administration method, administration time, administration route and excretion rate, treatment period, combination or concurrent use of drugs, and other factors well known in the medical field. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with the minimum amount without side effects, and this can be easily determined by those skilled in the art.
[0073] Hereinafter, the present invention will be described in more detail through examples. These examples are intended to more specifically illustrate the present invention, and the scope of the present invention is not limited to these examples.
[0074]
[0075] <Example 1> Preparation of Polysias extract
[0076] Polyscias (Polyscias fruticosa) was purchased from a local market in Quang Ning, Vietnam. 200 g of Polyscias root powder was extracted with 2 L of 94.5% ethanol at room temperature for 24 hours, and then filtered through filter paper (Whatman No. 2). The solvent was completely removed from the Polyscias ethanol extract using a vacuum rotary evaporator (N-1000, Rikakikai Co., Ltd, Tokyo, Japan).
[0077]
[0078] <Example 2> Preparation of Polysias lipid-soluble fraction
[0079] 2-1. Preparation of hexane fraction
[0080] The polysiaceae ethanol extract prepared in Example 1 was extracted with n-hexane solvent, and the solvent was completely removed using a vacuum rotary evaporator (N-1000, Rikakikai Co., Ltd, Tokyo, Japan) to prepare a hexane fraction.
[0081]
[0082] 2-2. Preparation of DCM fraction
[0083] The polysiaceae ethanol extract prepared in Example 1 was extracted with a dichloromethane solvent, and the solvent was completely removed using a vacuum rotary evaporator (N-1000, Rikakikai Co., Ltd, Tokyo, Japan) to prepare a DCM fraction.
[0084]
[0085] 2-3. Component analysis of fat-soluble fractions
[0086] Hydrophobic compounds present in the hexane fraction and DCM fraction obtained from the ethanol extract of Polyscias fruticosa were analyzed using GC-MS.
[0087] Specifically, the chemical compositions of the hexane fraction and the dichloromethane (DCM) fraction of Polysias root were identified using gas chromatography (Agilent 7890A, Agilent Technologies, CA, USA) combined with mass spectrometry (Agilent 5975C) (GC / MS). An Agilent J&W DB-5 ms fused silica capillary column (60 m × 0.25 mm × 0.25 μm) was used, and the temperature was set to 50°C for 3 min, 50–310°C at 5°C / min, and finishing at 310°C for 25 min. The carrier gas was Helium, the split flow was set to 1:20, the split mode was set to 1:20, and the flow rate was set to 1 mL / min. The temperatures of the transfer line and injector were set to 280°C. Masses were detected between 35 and 600 Da in a full scan at an ionization energy of 70 eV and a speed of 0.132 s / scan. Components were determined by comparing mass spectra with reference mass spectra using Agilent MassHunter libraries, including the National Institute of Standards and Technology (NIST) and Wiley libraries. Volatile compounds detected in the hexane and DCM fractions of P. fruticosa are shown in Tables 1 to 3 below.
[0088] As a result, as shown in Tables 1 to 3 and Figs. 1 and 2 below, the fat-soluble fraction of P. fruticosa roots contained a total of 42 compounds (fatty acids and esters (n=14), oxygenated hydrocarbons (n=4), polyphenols composed of phenol derivatives and lignans (n=15), polyacetylenes (n=1), sterols (n=3), terpenes (n=3), and other components showing characteristics of the Araliaceae family (n=2)), and fatty acids accounted for more than 50% of the total components analyzed.
[0089] Both fractions of P. fruticosa roots showed high contents of linoleic acid, palmitic acid, and oleic acid in that order, and in particular, compared to the P. fruticosa DCM fraction, polyphenol compounds were absent, but palmitic acid content was significantly higher.
[0090] The hexane fraction of P. fruticosa was found to contain long-chain saturated fatty acids that are actively involved in the metabolic pathways involving palmitic acid and stearic acid. Furthermore, phytosterols were abundant in P. fruticosa, and stigmasterol showed greater affinity for the hexane fraction than for the DCM fraction.
[0091]
[0092]
[0093]
[0094]
[0095]
[0096] <Experimental Example 1> Hepatoprotective mechanism of the lipid-soluble fraction of P. fruticosa roots in a D-GalN / LPS-induced liver injury model.
[0097] 1-1. Animal testing
[0098] Female C57BL / 6 mice (18–20 g) were purchased from HanaBio and used in the experiment. The mice underwent a one-week adaptation period before the experiment, during which they were allowed free access to food and water.
[0099] A mouse acute liver injury model was induced by intraperitoneal injection of a single dose of D-GalN / LPS (D-Galactosamine / Lipopolysaccharide; 300 mg / kg and 5 μg / kg, respectively) on the last day of oral administration of P. fruticosa. P. fruticosa ethanol extract (EtOH Extr.) and lipid-soluble components, hexane fraction (Hex fr.) and DCM fraction (DCM fr.), were orally administered once daily at a concentration of 100 and 200 mg / kg, and silymarin (SIL, positive control) at a concentration of 200 mg / kg for 15 days before intraperitoneal injection of D-GalN / LPS. Mice were sacrificed 6 hours after injection of D-GalN / LPS, and liver tissues and serum were obtained.
[0100]
[0101] 1-2. Histological analysis
[0102] Liver tissue was fixed in 10% phosphate-buffered formalin, embedded in paraffin blocks, and stained with hematoxylin and eosin (H&E).
[0103] As a result, as shown in Figs. 3 and 4, the D-GalN / LPS group showed inflammation and cell necrosis of the large portal vein and severe inflammatory cell infiltration (Fig. 3). Mice pretreated with the lipid-soluble fraction of P. fruticosa showed significantly less necrosis and degenerative changes and less inflammatory cell infiltration, which means that pretreatment with the lipid-soluble fraction of P. fruticosa lowers the histopathological score induced by D-GalN / LPS (Fig. 4).
[0104]
[0105] 1-3. Measurement of alanine transaminase (ALT) and aspartate transaminase (AST)
[0106] Serum ALT levels were tested and analyzed using the Alanine Aminotransferase (ALT or SGPT) Activity Colorimetric / Fluorometric Assay Kit (Biovision, #K752-100), and AST levels were tested and analyzed using the Aspartate Aminotransferase (AST or SGOT) Activity Colorimetric Assay Kit (Biovision, #K753-100) according to the manufacturer's instructions.
[0107] Additionally, liver damage was assessed by the levels of ALT and AST enzymes in serum.
[0108] As a result, as shown in Fig. 5, serum ALT and AST levels were significantly increased in the D-GalN / LPS group compared to the control group. In contrast, administration of P. fruticosa EtOH extract, hexane fraction, and DCM fraction significantly reduced ALT and AST levels (Fig. 5).
[0109]
[0110] 1-4. Measurement of inflammatory cytokine and NLRP3 inflammasome-related protein expression levels
[0111] The expression of inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-17, IL-23) and NLRP3 inflammasome (ASC, cleaved IL-1β) protein in liver tissue was measured by western blot.
[0112] As a result, as shown in Figs. 6 and 7, D-GalN / LPS increased the levels of proinflammatory cytokines such as IL-1β, IL-6, IL-17, and IL-23 in the liver. However, administration of the P. fruticosa EtOH extract, hexane fraction, and DCM fraction significantly decreased the levels of these cytokines (Fig. 6) and the expression of ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain) and cleaved IL-1β proteins (Fig. 7). These results indicate that administration of the lipid-soluble fraction of the P. fruticosa EtOH extract significantly inhibits D-GalN / LPS-induced NLRP3 inflammasome activity in the liver.
[0113]
[0114] 1-5. NF-κB signaling pathway
[0115] To determine the effect of P. fruticosa extract and its fractions on the NF-κB signaling pathway, which is an essential signaling system for innate immunity, the expression of p-p65 and p65 proteins related to the NF-κB signaling pathway in liver tissue was measured by western blot.
[0116] As a result, as shown in Figures 8 and 9, D-GalN / LPS significantly enhanced the NF-κB signaling pathway by increasing the phosphorylation of p65 in the liver. In contrast, treatment with the EtOH extract, hexane fraction, and DCM fraction of P. fruticosa was shown to reduce the p-p65 level induced by D-GalN / LPS, restoring it to the control level.
[0117]
[0118] 1-6. Antioxidant activity
[0119] To determine the effect of P. fruticosa extract and its fractions on antioxidant activity, the expression of antioxidant enzymes (CAT, GPx, SOD) proteins in liver tissue was measured by western blot, and SOD activity was tested and analyzed using an SOD Assay Kit (BO-SOD-250, BIOMAX / OxiTec) according to the manufacturer's manual.
[0120] As a result, as shown in Figures 10 to 12, D-GalN / LPS decreased the levels of antioxidant enzymes, including CAT, GPx, and SOD. However, treatment with the EtOH extract, hexane fraction, and DCM fraction of P. fruticosa significantly restored the protein levels of these antioxidant enzymes in liver tissue (Figures 10 and 11). In addition, these fat-soluble fractions restored the SOD activity reduced by D-GalN / LPS (Figure 12). In particular, it was confirmed that treatment with the DCM fraction exhibited higher antioxidant activity compared to the ethanol extract and hexane fraction.
[0121]
[0122] 1-7. Nrf2 signaling pathway
[0123] To determine the effects of P. fruticosa extract and its fractions on the Nrf2 signaling pathway, which is closely related to antioxidant activity, the expression of Nrf2, HO-1, and NQO-1 proteins related to the Nrf2 signaling pathway in liver tissue was measured by western blot.
[0124] As a result, as shown in Figures 13 and 14, treatment with D-GalN / LPS decreased the levels of Nrf2, HO-1, and NQO-1. However, treatment with the EtOH extract, hexane fraction, and DCM fraction of P. fruticosa significantly restored the reduced protein expression levels of Nrf2, HO-1, and NQO-1. In particular, the lipid-soluble fractions (hexane fraction and DCM fraction) showed better effects on inducing the Nrf2 signaling pathway compared to the ethanol extract.
[0125]
[0126] <Experimental Example 2> Anti-inflammatory mechanism of the lipid-soluble fraction of P. fruticosa root in a DSS-induced colitis model.
[0127] 2-1. Animal testing
[0128] Female C57BL / 6 mice (18-20 g) were purchased from HanaBio. The mice were allowed to adapt to the experiment for a week, during which time they were allowed free access to food and water. Acute colonic inflammation was induced by feeding drinking water containing 3% DSS (w / v) for 7 days, followed by drinking water without DSS (dextran sulfate sodium) for 3 days. The control group was fed drinking water without DSS. P. fruticosa ethanol extract (EtOH Extr.), fat-soluble components such as hexane fraction (Hex fr.) and DCM fraction (DCM fr.), and sulfasalazine (SULF, positive control) were orally administered at a concentration of 200 mg / kg once daily for 15 days, starting 5 days before feeding drinking water containing 3% DSS (w / v).
[0129]
[0130] 2-2. Histological analysis and inflammation scale evaluation
[0131] The disease activity index (DAI) was measured daily by checking the weight change of mice, stool hardness, and the presence of blood visually observed in the stool or anus. The score ranged from 0 to 4, with 4 indicating the most severe condition. After anesthesia, mice were sacrificed by cervical dislocation, and the intestines from the cecum to the anus were removed and measured in length. Colonic tissues were fixed in 10% phosphate-buffered formalin, embedded in paraffin blocks, and stained with hematoxylin and eosin (H&E).
[0132] As a result, as shown in Figs. 15 to 19, the mice in the control group did not show weight loss, diarrhea, colonic shrinkage, or mucosal damage during the experimental period. However, the mice in the DSS group showed a severe weight loss, which was significantly recovered by administration of the P. fruticosa EtOH extract, hexane fraction, and DCM fraction (Fig. 15). In addition, administration of the P. fruticosa EtOH extract, hexane fraction, and DCM fraction was shown to alleviate colonic inflammation by preventing the decreased colon length and DAI induced by DSS (Figs. 16 and 17). Mice administered the P. fruticosa EtOH extract, hexane fraction, and DCM fraction showed a significant decrease in mucosal damage and inflammatory cell infiltration in the mucosa and submucosa (Fig. 18). These results are consistent with those of P. Administration of fruticosaEtOH extract, hexane fraction and DCM fraction significantly reduced histological scores compared to mice with colonic inflammation (Fig. 19).
[0133]
[0134] 2-3. Measurement of inflammatory cytokine and NLRP3 inflammasome expression levels
[0135] To determine whether DSS-induced inflammatory responses and NLRP3 inflammasome activation were inhibited in the colon, the expression of inflammation-related markers (COX-2, IL-1β, IL-17, IL-23) and NLRP3 inflammasome (NLRP3) protein in colon tissue was measured by western blot.
[0136] As a result, as shown in Figures 20 to 22, DSS 3% treatment induced uncreative colitis, as evidenced by increased levels of proinflammatory factors including COX-2, IL-1β, IL-6, IL-17, and IL-23. However, administration of the EtOH extract, hexane fraction, and DCM fraction of P. fruticosa significantly inhibited the expression of DSS-induced inflammatory proteins (Figures 20 and 21). In addition, administration of the lipid-soluble fraction of P. fruticosa reduced DSS-induced NLRP3 inflammasome activation in colon tissue (Figure 22).
[0137]
[0138] 2-4. Antioxidant activity
[0139] Excessive ROS / RNS production significantly contributes to the inflammatory response and progression of inflammatory disorders. To evaluate the antioxidant activity of the lipid-soluble fraction of P. fruticosa administered to the colon, the expression of the antioxidant enzyme CAT (catalase) and the Nrf2, HO-1, and NQO-1 proteins associated with the Nrf2 signaling pathway were measured by western blot in colonic tissue.
[0140] As a result, as shown in Figures 23 and 24, the CAT expression level in the DSS-treated group was reduced compared to the control group, indicating oxidative stress in the colon. However, administration of the P. fruticosa EtOH extract, hexane fraction, and DCM fraction significantly restored the CAT expression level reduced by DSS (Figure 23).
[0141] As a key regulator of the cellular antioxidant defense system, Nrf2 is responsible for the transcriptional activation of phase II antioxidant enzymes. Administration of the lipid-soluble fraction of P. fruticosa activated the Nrf2 pathway by enhancing the expression of Nrf2 and HO-1 in the colon tissue of DSS-induced mice (Fig. 24).
[0142]
[0143] 2-5. Measurement of tight junction protein expression levels
[0144] Tight junctions of intestinal mucosal cells are crucial for protecting the body from stress stimuli associated with inflammation and infection. To confirm the anti-inflammatory effect of administration of the lipid-soluble fraction of P. fruticosa, the expression of ZO-1, Claudin, and Occludin proteins in colon tissue was measured by western blot, and an in vivo intestinal barrier permeability test was performed.
[0145] Intestinal barrier permeability was analyzed in vivo using FITC-labeled dextran. Specifically, mice were orally administered FITC-labeled dextran (60 mg / 100 g body weight), and serum obtained from blood samples was subjected to fluorescence measurement. Fluorescence intensity was measured at 485 nm excitation and 520 nm emission wavelengths, and the concentration of FITC-dextran was calculated using a standard curve generated by serial dilutions of FITC-dextran.
[0146] As a result, as shown in Figures 25 and 26, it was confirmed that the P. fruticosa EtOH extract, hexane fraction, and DCM fraction also maintained the epithelial barrier function by upregulating the expression of Occludin in the DSS-induced colonic inflammation model (Figure 25). As a result, DSS-induced permeability was significantly alleviated by administration of the P. fruticosa EtOH extract, hexane fraction, and DCM fraction (Figure 26).
Claims
1. A pharmaceutical composition for preventing or treating liver damage or colitis, comprising an extract of Polyscias fruticosa or a fraction thereof as an active ingredient.
2. In paragraph 1, A pharmaceutical composition characterized in that the above Polyscias fruticosa extract is prepared by extracting from at least one selected from the group consisting of roots, stems, leaves, flowers, and fruits.
3. In paragraph 1, The above extract is a pharmaceutical composition obtained by extracting Polyscias fruticosa with an ethanol solvent.
4. In paragraph 1 A pharmaceutical composition, wherein the above fraction is obtained by fractionating an ethanol extract of Polyscias fruticosa using a non-polar solvent.
5. In paragraph 4, A pharmaceutical composition, characterized in that the nonpolar solvent is at least one solvent selected from the group consisting of benzene, toluene, acetone, carbon tetrachloride, hexane, dichloromethane, chloroform, ether, methylene, and ethyl acetate.
6. In paragraph 1, A pharmaceutical composition characterized in that the above liver damage is induced by D-GalN (D-Galactosamine) and LPS (Lipopolysaccharide).
7. In paragraph 1, A pharmaceutical composition, wherein the colitis is selected from the group consisting of ulcerative colitis, inflammatory bowel disease, acute colitis, bacterial colitis, viral colitis, pseudomembranous colitis, chronic colitis, Crohn's disease, ischemic colitis, Behcet's colitis, drug-induced colitis, collagenous colitis, lymphocytic colitis, and radiation colitis.
8. A health functional food composition for preventing or improving colitis, comprising an extract of Polyscias fruticosa or a fraction thereof as an active ingredient.
9. A health functional food composition for protecting the liver, comprising an extract of Polyscias fruticosa or a fraction thereof as an active ingredient.
10. A method for preventing or treating liver damage or colitis, comprising administering to a subject the pharmaceutical composition of paragraph 1.
Citation Information
Patent Citations
Traditional Chinese medicine for treating acute hepatitis, chronic hepatitis and hepatic fibrosis
CN102512485A
Aralia maculata total saponin as well as preparation method and application thereof
CN115025141A
